-
-
Pfizer's Q1 2025 Financial report
Market Trend
Pfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
-
Eli Lilly's Q1 2025 Financial report
Market Trend
Eli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
-
-
Novartis's Q1 2025 Financial report
Market Trend
Novartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
-
-
WuXi AppTec's Q1 2025 Financial report
Market Trend
WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
-
-
-
The Cost of Attacking the Pharmaceutical Industry
Trump
Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
彭水|
周宁县|
临汾市|
千阳县|
重庆市|
会昌县|
壶关县|
天等县|
新河县|
于都县|
晋宁县|
汾西县|
桂平市|
桃园市|
通河县|
成都市|
墨玉县|
武义县|
桂东县|
融水|
依兰县|
隆安县|
乌兰县|
阿拉善盟|
偃师市|
合川市|
都匀市|
平安县|
鄂托克旗|
成武县|
双牌县|
合山市|
金昌市|
平凉市|
呼图壁县|
玉田县|
文安县|
昌平区|
沽源县|
金华市|
丰镇市|